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Abstract  
Background: The DAPT score identifies patients with expected benefit from extended dual 
antiplatelet therapy beyond 1 year after percutaneous coronary intervention (PCI). In a 
post-hoc analysis from the AFCAS registry, we explored the value of DAPT score to predict 
outcome in patients with atrial fibrillation (AF) undergoing PCI. 
Methods and results: Outcome measures included major adverse cardiac/cerebrovascular 
events (MACCE) [all-cause death, myocardial infarction, repeat revascularization, stent 
thrombosis, or stroke/transient ischemic attack] and bleeding events. At 12-month follow-
up, patients with a DAPT score ≥1 had a higher incidence of MACCE, all-cause death, 
myocardial infarction (p=0.004, p=0.006, and p=0.013, respectively), but a similar bleeding 
rate (p=0.66), versus those with a DAPT score <1. In a subgroup of patients at high risk of 
stroke who received triple therapy for 1 month only, DAPT score ≥1 was associated with a 
higher incidence of MACCE, all-cause death, myocardial infarction (p=0.002, p=0.015, and 
p=0.039, respectively), but a similar bleeding rate (p=0.81). 
Conclusions: In AF patients undergoing PCI, a DAPT score ≥1 was associated with a higher 
incidence of thrombotic events, and a similar incidence of bleeding events compared with a 
DAPT score <1. These results were consistent in patients at high risk of stroke who received 












Atrial fibrillation (AF) is the most common sustained arrhythmia with a prevalence of 1-2% 
in the European Union [1]. Coronary artery disease has been reported in 34% of patients 
with AF; and 21% need revascularization [2]. The optimal management of antithrombotic 
therapy in patients with AF who undergo percutaneous coronary intervention (PCI) is 
unknown. The European Society of Cardiology guidelines on the management of AF 
recommend that patients with AF who have ≥1 additional stroke risk factor who undergo 
elective PCI and stenting should receive triple therapy [oral anticoagulation (OAC), 
clopidogrel, and aspirin] for a short period, followed by a period of dual therapy (OAC plus a 
single antiplatelet) [3]. 
These patients frequently have thrombotic and bleeding events shortly after index 
procedure [4], and thus, there is an unmet clinical need for better risk prediction tools to 
identify who would benefit from longer versus shorter antiplatelet therapy in addition to 
OAC. The performance of bleeding risk prediction scores HAS-BLED, ATRIA, mOBRI and 
REACH was poor in detecting major bleeds in patients with AF undergoing PCI [5].  
The DAPT (Dual Antiplatelet Therapy) score is a clinical prediction rule based on 
ischemic and bleeding risk factors that helps discriminate patients with greater expected 
benefit versus those with greater expected harm from extended dual antiplatelet therapy 
beyond 1 year, among those who underwent coronary stenting, had no major ischemic or 





In this post-hoc analysis from the AFCAS registry, we explored the value of the DAPT 
score to predict thrombotic and bleeding events in patients with AF undergoing PCI. 
Methods 
Patient selection and study design 
The AFCAS (management of patients with Atrial Fibrillation undergoing Coronary Artery 
Stenting) registry is a prospective multi-center observational study that enrolled consecutive 
patients with AF who underwent PCI and stenting [4]. The inclusion criterion was 
ongoing/history of AF (paroxysmal, persistent, or permanent). The only exclusion criteria 
were unwillingness/inability to participate in the study or to give informed consent. In each 
participating center, PCI was performed according to local practice, and patients were 
followed up for 12 months. Peri-procedural and post-procedural antithrombotic regimens 
were at operator’s discretion. Follow-up was performed by telephone calls/clinic visits 
scheduled at 1, 3, 6, and 12 months after PCI. Patients were enquired about clinical 
outcome endpoints (described below), hospitalization, and medications. CHA2DS2-VASc and 
HAS-BLED scores were calculated to evaluate the individual risks for stroke and bleeding 
events, respectively. The DAPT score was calculated as previously described [6]. Briefly, the 
scoring system assigned 1 point each for myocardial infarction (MI) at presentation, prior MI 
or PCI, diabetes, stent diameter less than 3 mm, smoking, and paclitaxel-eluting stent; 2 
points each for history of congestive heart failure/low ejection fraction and vein graft 
intervention; −1 point for age 65 to younger than 75 years; and −2 points for age 75 years or 
older. 
Ethical standards 
This investigator-driven study was conducted according to the guidelines of the 1964 





participating centers. Informed written consent was obtained from every patient after full 
explanation of the study protocol. The AFCAS registry is registered with ClinicalTrials.gov 
under the identifier: NCT00596570. 
Study definitions and endpoints 
The primary outcome measures were: 1) major adverse cardiac/cerebrovascular events 
(MACCE), and 2) bleeding events during 12 months follow-up. The composite endpoint of 
MACCE was defined as the first occurrence of all-cause death, MI, repeat revascularization, 
stent thrombosis, or stroke/transient ischemic attack. MI was defined according to the Third 
Universal Definition [7]. Repeat revascularization was defined as PCI or coronary bypass 
surgery to treat significant stenosis (>50%) in the previously treated vessel. Stent 
thrombosis was adjudicated according to the criteria of definite or probable stent 
thrombosis described by the Academic Research Consortium [8]. Transient ischemic attack 
was defined as a transient (<24 hours) focal neurological deficit adjudicated by neurologist, 
whereas stroke was defined as a permanent focal neurological deficit adjudicated by 
neurologist and confirmed by computed tomography/magnetic resonance imaging. Bleeding 
events were defined according to the Bleeding Academic Research Consortium (BARC) 
criteria, and included events adjudicated as minor (BARC 2), and major (BARC 3a, 3b, 3c, and 
5) [9]. 
Statistical analysis 
Continuous variables were reported as the mean ± standard deviation. Categorical variables 
were described with absolute and relative (percentage) frequencies. Comparisons were 
performed using the unpaired 2-tailed t-test for continuous variables, and the Pearson chi-
square test or Fisher Exact test for categorical variables, as appropriate. The calibration of 





assessed using the Hosmer-Lemeshow “goodness-of-fit” test, estimating the calibration 
slope and assessing the calibration plot, while its discrimination ability was assessed using 
the receiver operating characteristic curve. MACCE at 12 months was considered as a binary 
endpoint since follow-up at 12 months was completed in all patients and no competing risk 
existed. The area under the curve (AUC) with 95% confidence interval (CI) was reported. The 
Youden’s test was used to identify the best cutoff value of the DAPT score in predicting 12-
month MACCE. This cutoff value was used to dichotomize the DAPT score. Statistical 
analyses were performed using SPSS software, version 20 (IBM SPSS Inc., Chicago, IL, USA) 
and easyROC software (http://www.biosoft.hacettepe.edu.tr/easyROC/). 
Results 
Baseline characteristics 
For the current analysis, we included 929 consecutive patients with AF who underwent PCI 
between October 2008 and August 2010 at 17 institutions, in 5 European countries. Mean 
age was 73.0 ± 7.9 years, 276 (29.7%) were females, 460 (49.5%) had permanent AF, 528 
(56.8%) were already receiving vitamin K antagonist (VKA) upon enrolment, 529 (56.9%) 
presented with acute coronary syndrome, 915 (98.5%) were at high risk of stroke (CHA2DS2-
VASc score >1), 709 (76.3%) were at high pre-estimated risk of bleeding (HAS-BLED score 
≥3). Mean peri-procedural International Normalized Ratio was 1.9 ± 0.7.  
The DAPT score showed a modest discriminatory ability and good calibration in predicting 
12-month MACCE (AUC 0.566, 95%CI 0.522-0.611, Hosmer-Lemeshow test: p=0.698, 
calibration slope: 0.966, Fig. ???).  and mortality (AUC 0.592, 95%CI 0.534-0.649, Hosmer-





Youden’s test showed that the best cutoff of the DAPT score in predicting MACCE was 1 
(sensitivity: 61.7%, specificity 50.2%, negative predictive value 82.5%, positive predictive 
value 25.6%). Further analyses were then performed using this cutoff value. 
In the whole cohort, the DAPT score showed normal distribution, with 445 (47.9%) patients 
having score <1. Patients with a DAPT score ≥1 were less often at high risk of stroke 
(p=0.046), and less often at high risk of bleeding, versus those with a DAPT score <1 
(p<0.001) (Supplementary Table 1). At 12-month follow-up, patients with a DAPT score ≥1 
had a higher incidence of overall MACCE, all-cause death, and MI (p=0.004, p=0.006, and 
p=0.013, respectively), but a similar rate of BARC 2-5 bleeding (p=0.66) compared with 
those with a DAPT score <1 (Table 1).  
Among the whole cohort, 78 (8.4%) had access site complications. In 851 patients 
without access site complications, the DAPT score also showed normal distribution, with 
406 (47.7%) patients having score <1. In this subgroup of patients, those with a DAPT score 
≥1 had a higher risk of stroke (p=0.03), and lower risk of bleeding (p<0.001) compared with 
those with a DAPT score <1 (Supplementary Table 2). At 12-month follow-up, patients with a 
DAPT score ≥1 had a higher incidence of overall MACCE (p=0.002), all-cause death 
(p=0.004), and MI (p=0.005), but a similar rate of BARC 2-5 bleeding (p=0.25) compared with 
those with DAPT score <1 (Table 2). 
Among 851 patients without access site complications, 307 (36.1%) patients received 
triple therapy (VKA, clopidogrel, and aspirin) for 1 month only. In these 307 patients, the 
DAPT score again showed normal distribution, with 167 (54.4%) patients having score <1. 
Moreover, in these patients, those with a DAPT score ≥1 were less often at high risk of 
bleeding (p=0.001), but had a similar risk of stroke (p=1.0) compared with those with a DAPT 





of stroke. We analyzed the clinical outcome stratified by the DAPT score ≥1 in 305 patients 
without access site complications who received triple therapy for 1 month only and were at 
high risk of stroke. The prescribed duration of antithrombotic medications stratified by a 
DAPT score ≥1 was comparable in this selected subgroup (Table 3). At 12-month follow-up, 
patients with a DAPT score ≥1 (n=139) had a higher incidence of overall MACCE, all-cause 
death, and MI (p=0.002, p=0.015, and p=0.039, respectively), a trend to more frequent 
revascularization events (p=0.054), but a similar rate of BARC 2-5 bleeding (p=0.81), versus 
those with a DAPT score <1 (n=166) (Table 4). Since the higher incidence of overall MACCE in 
these patients was driven by higher rates of all-cause death and MI, we explored the time of 
occurrence of these events in relation to the first 1 month (triple therapy). In all 305 
patients, 83.3% (25 out of 30 events) of all-cause death events occurred after the first 1 
month (75% in patients with DAPT score ≥1 versus 100% in patients with DAPT score <1, 
p=0.14); and 84.2% (16 out of 19 events) of MI events occurred after the first 1 month 
(84.6% in patients with a DAPT score ≥1 versus 83.3% in patients with DAPT score <1, p=1.0).  
Discussion 
Major findings 
In the current post-hoc analysis from the AFCAS registry, a DAPT score ≥1 compared with a 
score <1, was associated with a higher incidence of coronary thrombotic events, and a 
similar incidence of bleeding events. 
Our results were consistent in patients without access site complications. In a selected 
subgroup of patients without access site complications who were at high risk of stroke and 
received triple therapy for 1 month only, a DAPT score ≥1 compared with a score <1, was 
again associated with a higher incidence of coronary thrombotic events, with a similar 





month. A DAPT score ≥1 had modest accuracy to predict thrombotic and bleeding events at 
12-month follow-up. 
Antithrombotic regimen after coronary stenting in patients with AF 
There is some controversy on the optimal antithrombotic regimen in patients with AF who 
need lifelong oral anticoagulation, and undergo PCI or develop acute coronary syndrome. 
Most of the available data derive from small single-center retrospective cohorts or subgroup 
analysis of randomized trials [3]. Unfortunately, there are no adequately powered 
randomized trials that compare efficacy and safety for alternative antithrombotic regimens 
in patients with AF who undergo PCI or develop acute coronary syndrome. Unanswered 
questions include change of antithrombotic regimen over time, and the duration of each 
antithrombotic medication. The current European Society of Cardiology guidelines on the 
management of AF recommend that patients with AF at risk of stroke who undergo PCI or 
develop acute coronary syndrome should receive a short period of triple therapy (OAC, 
clopidogrel, and aspirin), followed by a period of dual therapy (OAC plus a single 
antiplatelet) [3]. In patients who undergo PCI, triple therapy should be considered for 1 
month (Class IIa, Level of Evidence B), followed by dual therapy; the duration of dual 
therapy being based on the bleeding risk: in those at low risk of bleeding, dual therapy 
should be considered till the end of 12 months; in those at high risk of bleeding, dual 
therapy should be considered till the end of 6 months (Class IIa, Level of Evidence C) [3]. In 
patients who develop acute coronary syndrome, triple therapy should be considered (Class 
IIa, Level of Evidence B), followed by dual therapy; the duration of triple therapy is based on 
the bleeding risk: in those at low risk of bleeding, triple therapy should be considered for 6 
months; in those at high risk of bleeding, triple therapy should be considered for 1 month; in 





Evidence C) [3]. In either case, antithrombotic regimen continued after 1 month was based 
on assessment of the individual bleeding risk.  
The weak Level of Evidence for recommending continued antithrombotic regimen 
after the first month reflects insufficiency of the available data. These recommendations are 
largely based on expert opinion, or extrapolation of data from observational studies, 
subgroup analysis, and one small randomized trial [10-13].  
Calculation of the HAS-BLED score has some limitations for everyday clinical use: e.g. 
confirming ‘Labile International Normalized Ratio’ (defined by ‘time in therapeutic range’ 
<60%) is not always feasible. The definition of abnormal liver or renal function needs specific 
laboratory measurements, and confirmation of alcohol usage history is often challenging. 
HAS-BLED as well as ATRIA, REACH, and mOBRI scores failed to predict bleeds in an earlier 
report from AFCAS registry [5], although HAS-BLED score did predict bleeding in another 
cohort of ACS [14]. 
In the current study, we employed the DAPT score – a newly introduced clinical risk 
prediction rule based on a constellation of both ischemic and bleeding risk factors – to 
identify patients at higher 12-month thrombotic risk among those with AF in need for OAC 
(CHA2DS2-VASc score >1) who underwent PCI with stenting (nearly 60% acute coronary 
syndrome) and already received triple therapy for 1 month. In this way, we explored 
whether the score meant for long-term risk assessment in an intermediate-risk patient 
cohort is valid for mid-term risk assessment in a high-risk cohort. We found that in these 
patients, a DAPT score ≥1 was associated with a higher incidence of coronary thrombotic 
events (death and MI), but with a similar incidence of bleeding events. Moreover, around 
80% of the coronary thrombotic events occurred after the first month. We opted to exclude 





antithrombotic regimen and the event rates might have been influenced by access site 
events, introducing selection bias. Given the comparable rates of bleeding events and the 
largely comparable distribution of the duration of prescribed antithrombotic medications 
between the 2 groups (Tables 3 and 4), there is some reason to suggest that those patients 
who had a DAPT score ≥1 may benefit from triple therapy extended beyond 1 month. This 
entails extending the duration of antiplatelet medications (mainly clopidogrel), given that 
the virtually all patients with a DAPT score ≥1 were prescribed lifelong VKA (Table 3). This 
could be viewed in light of the clinical presentation of the AFCAS cohort; nearly 60% 
presented with acute coronary syndrome: in these patients, extending the duration of triple 
therapy to 6 months – rather than 1 month – may be based on risk stratification for 
thrombotic and bleeding events by a DAPT score ≥1, instead of risk stratification for 
bleeding events by HAS-BLED score <3. Similar consideration might be held for patients 
undergoing PCI for stable angina. It should be noted that nearly one-fourth of the AFCAS 
cohort received drug-eluting stents; these were mostly first-generation devices at the time 
of patient enrolment in the AFCAS registry. Patients who received these devices needed 
extended duration of dual antiplatelet therapy, mainly clopidogrel. An important advantage 
of the DAPT score is that it accounts for the risk of bleeding. In the current report, patients 
with a DAPT score ≥1 were less often at high risk of bleeding (HAS-BLED score ≥3), and had 
comparable rates of bleeding events, versus those with a DAPT score <1. In such patients, 
extending the duration of triple therapy beyond 1 month might not increase the incidence 







The current study has all the inherent limitations of observational study design, including 
individual decision-making in treatment choice. This may introduce selection bias, even 
though the antithrombotic medications prescribed at discharge were comparable between 
the 2 subgroups. Another limitation is the heterogeneity of cohort among the participating 
centers, and some variations in peri-procedural routines. The statistical power of the 
current analysis is limited by the absolute low rates of stent thrombosis and stroke, and the 
relatively small sample size; therefore, lack of significant difference between comparison 
groups might be due to type II statistical error. Sample size requirement for external model 
validation requires at least 100 events in the validation dataset for reliable calculation of 
performance indices. For some outcome events, the number of events was lower than 100, 
therefore external validation for these outcome events might be less reliable. Moreover, 
although the DAPT score predicted coronary thrombotic events in a selected cohort, it was 
insufficient for prediction of bleeding events. The strength of the registry is enrolment of 
consecutive patients with the only exclusion criterion being unwillingness/inability to 
participate in the study. In this sense the registry cohort represents well real-world patients 
with AF referred for PCI. 
Conclusion 
In patients with AF who undergo PCI, the DAPT score showed modest discrimination and 
good calibration. However, a DAPT score ≥1 was associated with a higher incidence of 
coronary thrombotic events, and a similar incidence of bleeding events compared with 
DAPT score <1. These findings were consistent in a selected subgroup without access site 
complications who were at high risk of stroke and received triple therapy for 1 month only. 
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Table 1 Clinical outcome of the 2 groups stratified by DAPT score ≥1 in the whole cohort 
(n=929) 
 
DAPT score ≥1 
(N=484) 




MACCE 124 (25.6) 79 (17.8) 0.004 
All-cause mortality 68 (14.0) 37 (8.3) 0.006 
Myocardial infarction 37 (7.6) 17 (3.8) 0.013 
All revascularizations 44 (9.1) 29 (6.5) 0.14 
Stent thrombosis 8 (1.7) 7 (1.6) 0.92 
Stroke/arterial embolism 11 (2.3) 12 (2.7) 0.68 
BARC 2-5 Bleeding 85 (17.6) 83 (18.7) 0.66 
Variables are presented as frequency (percentage).  







Table 2 Clinical outcome of the 2 groups stratified by DAPT score ≥1 in patients without 
access site complications (n=851) 
 
DAPT score ≥1 
(N=445) 




MACCE 114 (25.6) 68 (16.7) 0.002 
All-cause mortality 63 (14.2) 32 (7.9) 0.004 
Myocardial infarction 34 (7.6) 13 (3.2) 0.005 
All revascularizations 40 (9.0) 25 (6.2) 0.12 
Stent thrombosis 7 (1.6) 5 (1.2) 0.67 
Stroke/arterial embolism 10 (2.3) 10 (2.5) 0.84 
BARC 2-5 Bleeding 51 (11.5) 57 (14.0) 0.25 
Variables are presented as frequency (percentage).  






Table 3 Prescribed duration of antithrombotic treatments at discharge in the 2 groups 
stratified by DAPT score ≥1 in patients without access site complications who were at high 
risk of stroke and received triple therapy for 1 month (n=305) 
 DAPT score ≥1 
(N=139) 
DAPT score <1 
(N=166) 
Prescribed aspirin duration   
    Lifelong 81 (59.7) 95 (57.2) 
    12 months 7 (5.0) 14 (8.4) 
    6 months 2 (1.4) 4 (2.4) 
    3 months 1 (0.7) 5 (3.0) 
    1 months 46 (33.1) 48 (28.9) 
Prescribed clopidogrel duration   
    12 months 11 (7.9) 15 (9.0) 
    9 months 1 (0.7) 0 (0) 
    6 months 1 (0.7) 1 (0.6) 
    3 months 2 (1.4) 9 (5.4) 
    1 months 124 (89.2) 141 (84.9) 
Prescribed VKA duration (n=245)   
    Lifelong* 98 (99.0) 142 (97.3) 
    3 months* 0 (0) 1 (0.7) 
    1 months* 1 (1.0) 3 (2.1) 
Continuous variables are presented as mean ± standard deviation, whereas categorical 





*The number of patients is 99 for patients with DAPT score ≥1, versus 146 for patients with 
DAPT score <1 







Table 4 Clinical outcome of the 2 groups stratified by DAPT score ≥1 in patients without 
access site complications who were at high risk of stroke and received triple therapy for 1 
month (n=305) 
 
DAPT score ≥1 
(N=139) 




MACCE 40 (28.8) 24 (14.5) 0.002 
All-cause mortality 20 (14.4) 10 (6.0) 0.015 
Myocardial infarction 13 (9.4) 6 (3.6) 0.039 
All revascularizations 16 (11.5) 9 (5.4) 0.054 
Stent thrombosis 3 (2.2) 2 (1.2) 0.66 
Stroke/arterial embolism 4 (2.9) 3 (1.8) 0.70 
BARC 2-5 Bleeding 18 (12.9) 20 (12.0) 0.81 
Variables are presented as frequency (percentage).  
BARC indicates Bleeding Academic Research Consortium; MACCE, major adverse cardiac and 
cerebrovascular events. 
 
 
